Introduction
============

Liver cancer is one of the common malignant tumors worldwide that is associated with very poor prognosis. A variety of factors contribute to liver cancer development, such as age, gender, obesity, diabetes and chronic hepatitis B virus (HBV) infection. Among the different factors that affect liver cancer progression, HBV infection exhibits the highest proportion and according to epidemiological data it accounts for 53% of all liver cancers in China ([@b1-ol-0-0-10291]). HBV is a hepadnavirus. The overlapping open reading frames of C, P, S and X are responsible for the genome assembly of HBV ([@b2-ol-0-0-10291],[@b3-ol-0-0-10291]). Previous studies have demonstrated that HBV participates in several cellular processes including proliferation, migration, invasion and apoptosis that are associated with liver cancer progression ([@b4-ol-0-0-10291]--[@b7-ol-0-0-10291]). The dominant theory suggests that HBV proteins, notably HBX, disturb the expression of proto-oncogenes or tumor suppressor genes resulting in the progression of liver cancer. However, the mechanism of this process remains unclear ([@b8-ol-0-0-10291]).

Accumulating evidence suggests that HBX contributes to liver cancer development by direct and indirect mechanisms. Nuclear factor-κB (NF-κB) and activator protein 1 (AP-1) can be activated by HBX that subsequently promotes cell proliferation ([@b9-ol-0-0-10291],[@b10-ol-0-0-10291]). HBX can also interact with different oncoproteins, such as Src and Ras to promote cell proliferation ([@b11-ol-0-0-10291],[@b12-ol-0-0-10291]).

The clathrin adaptor AP-1 complex is a primary regulator of vesicular transport and protein sorting. An integrated AP-1 complex comprises four subunits termed β1, γ, δ1 and μ1. The major function of the μ1 and β1 subunits involves the binding of transmembrane proteins by their sorting motifs, while γ and δ1 interact with clathrin and link transmembrane proteins with this protein ([@b13-ol-0-0-10291],[@b14-ol-0-0-10291]). μ1A and μ1B adaptin are two representative isoforms of the μ1 subunit that exhibit distinct expression ([@b15-ol-0-0-10291]). μ1B is mainly expressed in polarized epithelial cells compared with μ1A adaptin, which is ubiquitously expressed. Previous studies indicated that the μ1 subunit binding motif (YXXΦ) of the C-terminal region of the transmembrane proteins regulates their sorting or vesicular transport ([@b16-ol-0-0-10291]--[@b18-ol-0-0-10291]). In addition, recent studies have demonstrated new functions of the μ1 subunit in viral invasion, growth, cell proliferation and hyperplasia by its interaction with related transmembrane proteins ([@b19-ol-0-0-10291]--[@b22-ol-0-0-10291]). However, whether adaptin further participates in liver cancer development remains unknown.

The present study, aimed to investigate the effects of AP1M1 on liver cancer cell proliferation and to explore the associated mechanism of this process. It is reported that the μ1A adaptin AP1M1 is upregulated in liver cancer cells compared with the corresponding expression in normal hepatocytes. HBV facilitated AP1M1 expression in a c-Jun N-terminal kinase (JNK)-dependent manner. Overexpression of AP1M1 in HepG2 cells promoted its proliferation via the protein kinase B (AKT) pathway, while *AP1M1* silencing suppressed proliferation of HBV-transfected HepG2 cells.

Materials and methods
=====================

### Cell lines and reagents

The human non-tumor hepatic cell L02 and liver cancer cell lines HepG2 and Huh7 were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). HBV genome (pUC18-HBV1.2) transfected HepG2 (HepG2.215) was from the Peking University Hepatology Institute (Beijing, China). HBX deficiency HepG2.215 (HepG2.215ΔHBX) and HBX overexpression HepG2 (HepG2-HBX) were obtained as previously described and expression of HBX in the cells mentioned above was detected ([@b23-ol-0-0-10291],[@b24-ol-0-0-10291]). The cells were cultured in Dulbecco\'s Modified Eagle Medium (high glucose) (HyClone; GE Healthcare Life Sciences, Logan UT, USA) supplemented with penicillin-streptomycin and 10% fetal bovine serum (Serana Europe GmBh, Pessin, Germany) at 37°C in 5% CO~2~. For AKT, JNK or nuclear factor (NF)κB inhibitor treatment, 10 mM LY294002 (Sigma-Aldrich, Merck KGaA), 10 mM SP600125 (Sigma-Aldrich, Merck KGaA) and 5 mM BAY11-7082 (Sigma-Aldrich; Merck KGaA) in DMSO were administrated to the cells with a final concentration of 10 µM LY294002, 10 µM SP600125 and 5 µM BAY11-7082 respectively in 37°C and 5% CO~2~ atmosphere. After 24 h, the cells were washed twice with PBS and collected for subsequent detection. In the cell viability assay, LY294002 was administrated immediately after cell adherence and maintained to the end.

### Plasmids

For *AP1M1* overexpression plasmid construction, the human *AP1M1* open reading frame was amplified from cDNAs extracted from HepG2 with the following primers 5′-CTA*[GCTAGC]{.ul}*ATGTCCGCCAGCGCCGTCTAC-3′, 5′-CCG*[GAATTC]{.ul}*TCACTGGGTCCGGAGCTGGTAATCT-3′ and cloned into eukaryotic vector pcDNA3.1^(+)^ by restriction enzymes *Nhe*I and *EcoR*I. For *ap1m1* silencing, the small interfering (si)RNAs against *AP1M1* (siRNA1, 5′-GCTATCACGCTTCGAGAATGA-3′ and siRNA2: 5′-GGCATCAAGTATCGGAAGA-3′) were administrated to HepG2.215. For HBX overexpression plasmid construction, the full length HBX sequence was amplified from the HBV genome with the following primers 5′-TGTG*[AAGCTT]{.ul}*ATGGCTGCTAGGC-3′, 5′-TGT G*[GAATTC]{.ul}*TTAGGCAGAGGTG-3′ and cloned into pcDNA3.1^(+)^ by restriction enzymes *Hind*III and *EcoR*I. The pUC18-HBV1.2-ΔHBX plasmid, a vector containing a synthetic HBV mutant with a deleted HBX gene, was constructed in Transheep Bio (Shanghai, China, <http://www.transheep.com/>) and was used for HepG2.215ΔHBX construction. The transfection was done using Lipo2000 (Thermo Fisher Scientific, Inc., Waltham, USA) according to the manufactory\'s protocol. The *AP1M1* overexpression liver cancer cell HepG2-OEAP1M1, control HepG2-NC were obtained after screening with 500 µg/ml G418.

### Western blotting

Cells were homogenized in RIPA lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China) containing with freshly added protease inhibitors and phosphatase inhibitor. Protein was analyzed with a bicinchoninic acid assay (Beyotime Biotechnology, Shanghai, China) to quantify protein concentration. A total of 30 µg of total protein was loaded per lane. Proteins were resolved by 10% SDS-PAGE and transferred to PVDF membranes. 3% BSA (Solarbio, Beijing, China) was administrated at room temperature for 90 min to block nonspecific binding sites. The anti-AP1M1 rabbit polyclonal antibodies (ab111135) was purchased from Abcam (Cambridge, UK), the β-actin antibody (AC026) was purchased from Abclonal (Wuhan China), the antibodies for total JNK (\#9252), AKT (\#4691) and phosphorylated JNK (\#4668) and AKT (\#4060) were purchased from CST (Boston, MA, USA). The final dilution of AP1M1 antibodies was 1:500, β-actin antibody was 1:5,000, the others were 1:1,000. After incubation with the primary antibodies overnight at 4°C, the PVDF membranes were washed with TBST buffer thrice and incubated with 1:1,000 diluted HRP-linked secondary antibody (\#7074) at room temperature for 60 min. The labeled bands were detected with ECL Plus Western blotting detection kit (Beyotime Institute of Biotechnology).

### Reverse transcription-quantitative PCR (RT-qPCR)

Total RNA was extracted from cells homogenized in TRIzol (Thermo Fisher Scientific, Inc.; 3 replica wells for each cell line). A total of 1 µg of purified RNA was used for reverse transcription with a High-Capacity cDNA Reverse Transcription kit (Takara, Bio, Inc., Otsu, Japan) at 37°C for 15 min. The resulting cDNA was used for quantitative PCR on a real-time PCR detection system (Roche LightCycler480) with two-step method. The cycling conditions were: Initial denaturation 95°C for 120 sec, then 40 cycles of 95°C for 10 sec, 60°C for 20 sec. Relative mRNA expression level was determined using the 2^−ΔΔCq^ method with *β-actin* as the internal reference control ([@b25-ol-0-0-10291]). The sequences of primers used were as following: *AP1M1* (5′-GACCGCACCATCTCCTTCATCC-3′, 5′-TTGACCGCCGCTTGAACTGG-3′); *β-actin* (5′GGCATCGTGATGGACTCCG3′, 5′-GCTGGAAGGTGGACAGCGA-3′); *HBX* (5′-GTGAAGCTTATGGCTGCTAGGC-3′, 5′-GTGGAATTCTTAGGCAGAGGTG-3′).

### Cell viability assay

A density of 2×10^4^ cells/ml cells were prepared and 100 µl of cell suspension was placed into 96-well plates (6 replica wells for each cell line). The number of viable cells was determined by Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan) according to the manufacturer\'s protocol.

### Colony formation assay

A total of \~200 cells of each cell line were added to 6-well culture plate with three paralleled repeats. After incubation at 37°C in 5% CO~2~ for two weeks, the cells were washed with PBS and stained with Crystal Violet Staining Solution for 10 min at room temperature. The number of colonies containing at least 30 cells was counted under a white light microscope at a magnification of ×100.

### Prediction of transcription factors binding sites on promoter

The 2,000 bp sequences upstream of *AP1M1* transcription start site was used to predict the key transcription factors of regulating AP1M1 expression with online software (<http://jaspar.binf.ku.dk/>).

### Dual luciferase assay

The *AP1M1* promoter (2,000 bp upstream of transcription start site) was cloned into the multiple cloning sites of pGL3-basic reporter vector (Promega Corporation, Madison, WI, USA). A total of 1×10^5^ cells of each cell line were seeded into 12-well plates with three paralleled repeats and co-transfected with reporter plasmid (encoding firefly luciferase) and internal reference control vector (encoding renilla luciferase) using Lipofectamine 2000 (Thermo Fisher Scientific, Inc., Waltham, USA). After 48 h, luciferase assay was carried out using the Dual Luciferase Assay kit (Promega Corporation) following the manufacturer\'s protocol. The renilla luciferase activity was used for normalization. The relative luciferase activity of HepG2 transfected with pGL3-*AP1M1* promoter was defined as 100%.

### Public expression profile data analysis

The 27 expression profile data of acute liver failure patients (GDS4387) uploaded by Nissim *et al* ([@b26-ol-0-0-10291]) were cited from NCBI GEO Profiles database (<https://www.ncbi.nlm.nih.gov/geoprofiles/85359804>). Among all the 27 samples, 10 samples were HBV-negative while 17 were HBV-positive. Value of *AP1M1* transcription was analysed by Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA) software.

### Statistical analysis

Data were analyzed using Prism (GraphPad Software, Inc.) and are presented as the mean ± standard error of the mean. Statistical significance was determined using the unpaired two-tailed Student\'s t test for single variables and two-way analysis of variance followed by Bonferroni posttests for multiple variables. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### HBV upregulates AP1M1 expression in liver cancer cells

In the authors\' recent study, an Affymetrix GeneChip Human Gene 1.0 ST array was performed to investigate the role of HBV in the genetic alteration of liver cancer cells ([@b23-ol-0-0-10291]). In addition to interleukin-7R, it was reported previously that the transcription of the AP-1 complex subunit mu-1 coding gene *AP1M1* was also upregulated in pUC18-HBV1.2 transfected liver cancer cells. To further determine whether AP1M1 was upregulated in HBV-positive liver cancer cells, the transcriptional levels of *AP1M1* in human hepatocyte lineage L02 cells and in Huh7, HepG2 and HepG2.215 liver cancer cells (stable transfection with the HBV genome) were initially tested. Liver cancer cells expressed high levels of AP1M1, while hepatocytes expressed relatively lower levels of this protein. In addition, HBV further increased *AP1M1* transcription resulting in significantly increased levels of this gene in the HepG2.215 cell line compared with those noted in HepG2 cells (P\<0.001; [Fig. 1A](#f1-ol-0-0-10291){ref-type="fig"}). AP1M1 protein expression was further increased in liver cancer cells and was significantly increased following transfection with the HBV genome (P\<0.05; [Fig. 1B and C](#f1-ol-0-0-10291){ref-type="fig"}).

To determine whether HBV infection could alter *AP1M1* transcription in the liver, the expression profile data (GDS4387) of 27 samples from acute liver failure patients with or without HBV infection was analysed. The data were uploaded by Nissim *et al* ([@b26-ol-0-0-10291]). In agreement with the observations of the present study, HBV infection facilitated *AP1M1* expression in the liver samples ([Fig. 1D](#f1-ol-0-0-10291){ref-type="fig"}). Taken collectively, these data suggested that *AP1M1* was upregulated in liver cancer and that HBV infection could further facilitate its expression in liver cancer cells.

### HBV promotes proliferation of liver cancer cells through upregulation of AP1M1

Numerous studies have confirmed that HBV infection and notably HBX expression, promotes hepatocellular carcinoma (HCC) aggravation by facilitating HCC cell proliferation and invasion ([@b21-ol-0-0-10291]--[@b23-ol-0-0-10291]). The exact mechanism of this process remains unclear ([@b27-ol-0-0-10291]--[@b29-ol-0-0-10291]). The contribution of the increased levels of AP1M1 that occur during HBV infection on the proliferation of liver cancer cells was investigated. *AP1M1* expression was knocked down by siRNAs transfection. As presented in [Fig. 2A and B](#f2-ol-0-0-10291){ref-type="fig"}, the expression levels of AP1M1 were reduced following administration with siRNAs, notably siRNA1 and therefore siRNA1 was used in the following study. The cell proliferation was subsequently tested by cell viability and colony formation assays. Silencing of *AP1M1* could significantly (P\<0.001) suppress the proliferative ability of HBV-transfected liver cancer cells (HepG2.215). This led to \~25% cell growth reduction compared with the control cells ([Fig. 2E and F](#f2-ol-0-0-10291){ref-type="fig"}).

To further dissect whether AP1M1 overexpression could promote liver cancer cell proliferation, the total *AP1M1* expression cassette was inserted into the eukaryotic cell expression vector pcDNA3.1 and then transfected into HepG2 cells. The stable transfected HepG2-OEAP1M1 cells were established that exhibited AP1M1 overexpression ([Fig. 2C and D](#f2-ol-0-0-10291){ref-type="fig"}). Concomitantly, the control cells HepG2-NC were also established ([Fig. 2C and D](#f2-ol-0-0-10291){ref-type="fig"}). Cell viability and colony formation assays indicated that AP1M1 could significantly promote HepG2 proliferation (P\<0.001). Compared with HepG2-NC, cell growth of HepG2-OEAP1M1 cells was increased \~20% ([Fig. 2E and F](#f2-ol-0-0-10291){ref-type="fig"}). Taken collectively, these findings suggested that AP1M1 was one of the crucial factors involved in the enhanced proliferation of liver cancer cells caused by HBV infection.

### HBX is the major functional protein in HBV regulating AP1M1 expression

HBV possesses four overlapping open reading frames, namely C, P, S and X ([@b24-ol-0-0-10291]--[@b26-ol-0-0-10291]). The coding protein HBX was reported to possess multiple transcriptional regulatory activities ([@b2-ol-0-0-10291],[@b30-ol-0-0-10291],[@b31-ol-0-0-10291]). The present study explored whether HBX alone could facilitate AP1M1 expression. In order to address this hypothesis, HBX overexpressing HepG2 cells (HepG2-HBX) and HBX deficient HepG2.215 cells (HepG2.215ΔHBX) were constructed ([Fig. 3A](#f3-ol-0-0-10291){ref-type="fig"}). While overexpression of HBX facilitated AP1M1 expression, HBX deficiency in HepG2.215 cells reduced AP1M1 protein levels ([Fig. 3B](#f3-ol-0-0-10291){ref-type="fig"}). In accordance with the western blotting results, quantitative PCR indicated that transcription of *AP1M1* in HepG2-HBX cells was \~1.5 times increased compared with in HepG2 cells. The data indicated that the expression of AP1M1 was downregulated to \~30% in HepG2.215ΔHBX cells compared with that noted in HepG2.215 cells ([Fig. 3C](#f3-ol-0-0-10291){ref-type="fig"}). The interaction of HBX with the *AP1M1* promoter by luciferase assays was further examined. The *AP1M1* promoter-driven coding sequence was transfected into liver cancer cells and the luciferase activity was determined as described in the Materials and methods section. HepG2-HBX and HepG2.215 cells demonstrated indiscriminate luciferase activity levels, while HepG2 and HepG2.215-ΔHBX exhibited significantly lower activity levels (P\<0.05) compared with HepG2-HBX and HepG2.215 cells ([Fig. 3D](#f3-ol-0-0-10291){ref-type="fig"}). Taken collectively, the data indicated the role of HBX in facilitating AP1M1 expression in liver cancer cells.

However, the exact way by which the elevated expression of AP1M1 promotes liver cancer cell proliferation remains unknown. Yoneyama *et al* ([@b21-ol-0-0-10291]) demonstrated that AP1M1 binds to the YXXΦ motifs of insulin receptor substrate (IRS-1) and subsequently activates the phosphotidylinositol 3 kinase (PI3K)-AKT pathway in order to induce cell proliferation in L6 myoblasts. Whether the expression of the human AP1M1 protein could also enhance PI3K-AKT activity and induce cell proliferation was examined. Total protein was extracted from HepG2, HepG2-OEAP1M1, HepG2.215 and HepG2.215-siAP1M1 cells and the phosphorylation of AKT was detected by western blotting. AP1M1 did not alter the amount of total AKT ([Fig. 3E](#f3-ol-0-0-10291){ref-type="fig"}). However, the phosphorylation of AKT ([Fig. 3E](#f3-ol-0-0-10291){ref-type="fig"}) was altered. Overexpression of AP1M1 increased the phosphorylation of AKT while its knockdown had the opposite effect. The data suggested that the human AP1M1 protein could activate the PI3K-AKT pathway. To investigate whether phosphorylation of AKT was required for liver cancer cell proliferation, the PI3K-AKT inhibitor LY294002 was administrated to HepG2-OEAP1M1 cells and a cell viability assay was performed. The data indicated that PI3K-AKT inhibition could significantly reduce cell viability (P\<0.001). Moreover, the reduction effect was more profound in HepG2-OEAP1M1 cells compared with in HepG2-NC cells ([Fig. 3F](#f3-ol-0-0-10291){ref-type="fig"}). This implied that the activation of the PI3K-AKT pathway was required for the regulation of liver cancer cell proliferation by AP1M1.

### HBV facilitates AP1M1 expression via the JNK pathway

Furthermore, the signaling pathways required for HBV and/or HBX regulation of AP1M1 transcription was investigated. It was reported that HBV or HBX alone could activate multiple signaling pathways, such as the NFκB, Wnt, PI3K-AKT and mitogen associated protein kinase (MAPK) pathways ([@b32-ol-0-0-10291]--[@b35-ol-0-0-10291]). To determine the key-signaling pathway, which regulated the expression of AP1M1, we initially conducted a prediction analysis of the binding sites of downstream transcription factors from representative pathways using online software (<http://jaspar.binf.ku.dk/>). As presented in [Fig. 4A](#f4-ol-0-0-10291){ref-type="fig"}, the binding sites for NFκB1, c-Jun and c-Fos are located in the AP1M1 promoter region. Therefore, whether inhibition of the NFκB or the JNK pathways could downregulate the expression levels of AP1M1 was tested. The NFκB inhibitor BAY11-7082 did not suppress AP1M1 expression significantly ([Fig. 4B](#f4-ol-0-0-10291){ref-type="fig"}). However, following inhibition of JNK phosphorylation, AP1M1 expression declined notably in HepG2.215 cells ([Fig. 4C-E](#f4-ol-0-0-10291){ref-type="fig"}). These results were noted at the transcriptional ([Fig. 4D](#f4-ol-0-0-10291){ref-type="fig"}) and protein level ([Fig. 4C and E](#f4-ol-0-0-10291){ref-type="fig"}). Taken collectively, these data implied that JNK may be the key signaling protein involved in the HBV-mediated regulation of AP1M1 expression.

Discussion
==========

Although previous studies have demonstrated that HBV infection can increase the risk of liver cancer, the exact molecular mechanism of this process remains undiscovered ([@b1-ol-0-0-10291],[@b2-ol-0-0-10291],[@b5-ol-0-0-10291],[@b6-ol-0-0-10291]). In the present study, it was demonstrated that AP1M1 acted as a cancer-promoting factor. AP1M1 overexpression promoted HepG2 proliferation, while its knockdown suppressed HepG2.215 proliferation. The data supported a model in which HBV infection or HBX expression upregulated AP1M1 expression by the JNK pathway. The abnormal expression of adaptin in turn promoted cell proliferation. Moreover, the results of the presented study indicated that the PI3K-AKT pathway was involved in this process and that overexpression of AP1M1 enhanced AKT phosphorylation in liver cancer cells. In contrast to AP1M1 overexpression, the silencing of *AP1M1* inhibited AKT phosphorylation in the HBV-transfected liver cancer cells. These findings expand understanding of the function of adaptin in liver cancer.

In the past decades, cell biologists have unraveled the mechanism and specific function of adaptin ([@b30-ol-0-0-10291]--[@b32-ol-0-0-10291]). The canonical biological function of adaptin involves vesicular transport and protein sorting ([@b36-ol-0-0-10291]--[@b38-ol-0-0-10291]). Recently, novel biological roles of adaptin were identified, such as viral invasion, cell growth and hyperplasia. Using an *in vitro* cell culture system, it was demonstrated that the upregulation of human μ1A adaptin AP1M1 could promote liver cancer cell proliferation, which was in line with its homologous form reported in rats that regulated cell proliferation in L6 myoblasts ([@b21-ol-0-0-10291]). Hase *et al* ([@b22-ol-0-0-10291]) demonstrated the opposite function of the homologous form of AP1M1 in rodents. Specifically, it was demonstrated that adaptin μ1B deficiency in mice caused intestinal crypt hyperplasia with villous dysplasia owing to excessive proliferation of epithelial cells. The expression levels of μ1B adaptin AP1M2 were further examined in HepG2.215 and no differential expression was noted between HepG2 and HepG2.215 cells regarding *AP1M2* mRNA levels (data not shown). The data implied that only the expression of AP1M1 was regulated by HBV or HBX. This process promoted cell proliferation in HBV-positive liver cancer.

Current studies have demonstrated a variety of signaling pathways involved in HBV infection and liver cancer progression, including the NFκB, Wnt, PI3K-AKT, MAPK and Notch1 pathways ([@b31-ol-0-0-10291]--[@b34-ol-0-0-10291]). However, a limited number of studies have examined the interaction of these signaling pathways with AP1M1 or its homolog. Therefore, the key transcription factors involved in the signaling of the aforementioned pathways were initially investigated. Several NFκB1, c-Jun and c-Fos binding sites were predicted in the *AP1M1* promoter region. Subsequently, the pathway inhibitor was administered. Consistent with previous studies on other types of cancer cells ([@b39-ol-0-0-10291],[@b40-ol-0-0-10291]), the NFκB inhibitor BAY11-7082 suppressed proliferation of HepG2.215 and HepG2 cells, although no distinct difference was noted regarding *AP1M1* levels. Given that JNK is one of the most important regulators of the AP-1 complex assembly by c-Jun and c-Fos ([@b41-ol-0-0-10291]), the effect of the JNK pathway on *AP1M1* transcription was further tested and it was demonstrated that inhibition of JNK activity by SP600125 downregulated AP1M1 mRNA and protein levels. It is possible that the regulation of AP1M1 expression is a complex process and that it is associated with multiple factors. JNK is possibly one of the key factors regulating HBV/HBX-induced AP1M1 expression. Whilst at the same time, JNK was reported to be activated by HBV/HBX and subsequently induced the proliferation of liver cancer cells ([@b5-ol-0-0-10291],[@b42-ol-0-0-10291],[@b43-ol-0-0-10291]). However, the whole mechanism of JNK inducing liver cancer cells proliferation remains to be clarified. In the present study it was reported that one of the outcomes of activation of JNK pathway by HBV/HBX was the upregulation of AP1M1 and the upregulation of AP1M1 promoted liver cancer cells proliferation.

Previous studies have suggested that μ1 adaptin impacts cell proliferation and growth in rodents and plants ([@b20-ol-0-0-10291]--[@b22-ol-0-0-10291]). Yoneyama *et al* further demonstrated that this function was associated with IRS-1 and that it subsequently activated the PI3K-AKT pathway in rat myoblasts ([@b21-ol-0-0-10291]). The present study confirmed this finding in human liver cancer cells that overexpressed AP1M1 and found that this increased expression activated the AKT protein. In contrast to this activation, the knockdown of AP1M1 inhibited AKT phosphorylation. Whether interaction of AP1M1 and IRS-1 accounts for the activation of PI3K-AKT in liver cancer cells is still unknown.

Taken together, the results suggest that HBX can promote AP1M1 expression via the JNK pathway. Moreover, the increased expression of AP1M1 accelerated liver cancer cell proliferation leading to liver cancer progression. The results presented in the current study were derived from *in vitro* experiments. Whether overexpression of AP1M1 promotes liver cancer proliferation *in vivo* is not clear. In addition, HepG2, which was the main cell line used in the present study has now been demonstrated to be derived from a hepatoblastoma origin. The incidence of hepatoblastoma has not been associated with HBV infection. However, the GeneChip data of the hepatocyte-derived carcinoma cell line Huh7 that have been reported from the authors\' previous study ([@b23-ol-0-0-10291]), further indicated that transcription of *AP1M1* was upregulated in pUC18-HBV1.2 transfected Huh7 cells compared with the control Huh7 cells. In non-cancerous liver samples derived from acute liver failure patients, HBV infection facilitated *AP1M1* transcription. Therefore, HBV infection can facilitate AP1M1 expression in liver cells. The results of the present study expand the understanding of the biological functions of adaptin in liver cancer. Further studies on the clinical application of AP1M1 may provide new therapeutic targets for HBV-positive liver cancer treatments.
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![AP1M1 is upregulated in HBV-positive liver cancer cells. (A) Relative quantity of *AP1M1* mRNA levels from L02, Huh7, HepG2 and HepG2.215 cells. (B) AP1M1 protein expression analysis was detected by western blotting in L02, Huh7, HepG2 and HepG2.215 cells. (C) The quantification of the proteins was performed by densitometry. (D) The relative transcription of *AP1M1* in liver tissues of acute liver failure patients with or without HBV infection. \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001. HBV, hepatitis B virus.](ol-18-01-0456-g00){#f1-ol-0-0-10291}

![Upregulation of AP1M1 mediated by HBV promotes liver cancer cell proliferation. (A) Western blot analysis of AP1M1 from HepG2.215 cells with or without siRNA and (B) quantification of the proteins was performed by densitometry. (C) AP1M1 protein expression by western blot analysis in HepG2 cells overexpressing AP1M1 and control cells. (D) The quantification of the proteins was performed by densitometry. (E) Cell Counting Kit-8 and (F) colony formation assay analysis of cell proliferation among HepG2-NC, HepG2-OEAP1M1, HepG2.215 and HepG2.215-siAP1M1 cells. \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001. HBV, hepatitis B virus; si, small interfering; NC, negative control.](ol-18-01-0456-g01){#f2-ol-0-0-10291}

![HBX facilitates AP1M1 expression in liver cancer cells. (A) HBX mRNA was detected by reverse transcription-PCR. (B) AP1M1 protein expression analysis by western blotting of HepG2-NC, HepG2-HBX, HepG2.215 and HepG2.215ΔHBX cells. (C) Quantitative PCR analysis of *AP1M1* transcription in HepG2-NC, HepG2-HBX, HepG2.215 and HepG2.215ΔHBX cells. (D) Dual luciferase assay analysis of *AP1M1* promoter activity in HepG2-NC, HepG2-HBX, HepG2.215 and HepG2.215ΔHBX cells. (E) Western blot analysis of total and phosphorylated AKT in HepG2-NC, HepG2-OEAP1M1, HepG2.215 and HepG2.215-siAP1M1 cells. (F) Cell Counting Kit-8 assay analysis of cell proliferation in HepG2 and HepG2.215 cells treated with or without LY294002. \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001. HBV, hepatitis B virus; p-AKT, phosphorylated protein kinase B; NC, negative control; si, small interfering.](ol-18-01-0456-g02){#f3-ol-0-0-10291}

![HBV upregulated AP1M1 expression in a JNK-dependent manner. (A) The transcription factor binding sites were scanned using the JASPAR online software. (B) Analysis of *AP1M1* levels from HepG2 and HepG2.215 cells treated with BAY11-7082 by quantitative PCR. (C) Western blot analysis of total and phosphorylated JNK in HepG2 and HepG2.215 treated with or without Sp600125. (D) Quantitative PCR analysis of *AP1M1* transcription in HepG2 and HepG2.215 cells treated with Sp600125. (E) AP1M1 protein expression analysis by western blotting. The samples were derived from HepG2 and HepG2.215 cells treated with or without Sp600125. \*P\<0.05 and \*\*P\<0.01. NF, nuclear factor; HBV, hepatitis B virus; p-JNK, phosphorylated C-Jun N-terminal kinase; UTR, untranslated region.](ol-18-01-0456-g03){#f4-ol-0-0-10291}
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